Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

科研成果: 期刊稿件 › 文章 › 同行评审

!!!ASJC Scopus Subject Areas

@article{44782aa16f1d4973bb2c1d8e0fd10438,

title = "Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX",

note = "Publisher Copyright: {\textcopyright} 2020, The Author(s).",

year = "2020",

month = nov,

day = "1",

doi = "10.1038/s41408-020-00375-2",

language = "English",

volume = "10",

journal = "Blood Cancer Journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "11",

}

TY - JOUR

T1 - Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma

T2 - a cytogenetic subgroup analysis of POLLUX

PY - 2020/11/1

Y1 - 2020/11/1

UR - http://www.scopus.com/inward/record.url?scp=85094936712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85094936712&partnerID=8YFLogxK

U2 - 10.1038/s41408-020-00375-2

DO - 10.1038/s41408-020-00375-2

M3 - Article

C2 - 33149130

AN - SCOPUS:85094936712

SN - 2044-5385

VL - 10

JO - Blood Cancer Journal

JF - Blood Cancer Journal

IS - 11

M1 - 111

ER -